Ross Levine

Ross Levine has been at the forefront of understanding how epigenetic mutations drive hematologic malignancies, particularly the discovery and characterization of DNMT3A mutations as the most common somatic mutation in acute myeloid leukemia and clonal hematopoiesis of indeterminate potential. His laboratory elucidated how DNMT3A R882H dominant-negative mutations disrupt de novo DNA methylation, creating a hypomethylated epigenetic landscape that promotes self-renewal of hematopoietic stem cells. He has also contributed extensively to understanding IDH1/IDH2 mutations that produce the oncometabolite 2-hydroxyglutarate, inhibiting TET enzymes and causing a hypermethylation phenotype in AML and glioma.